Our round-up of biotech financings is led this week by Braveheart Bio, a San Francisco biotech that has launched with $185 million, a lead drug for hypertrophic cardiomyopathy (HCM), and Biogen CEO ...
The character the actor essays in the film has been inspired by Major Mohit Sharma, even though director Aditya Dhar has denied that it’s based on his life ...
Ukrainians on Saturday (November 29) said they saw no end to the war after Russia launched a vast, deadly air attack which killed three people and wounded nearly 30, officials said. Kyiv residents ...
She's just passed away. She's no longer with us. She's looking down on us right now. Her parents are with her. It's just ...
Bristol Myers Squibb currently has the only drug approved specifically for treating obstructive hypertrophic cardiomyopathy, a debilitating disorder that can progress to heart failure. But safety ...
With $185 million in series A funding and an army of experienced leaders in its ranks, Braveheart Bio is setting off to joust with big names in an emerging heart disease drug arena. Backed by ...
Board to include Chris Viehbacher as Chair, with investor syndicate led by Andreessen Horowitz, Forbion, and OrbiMed with participation from Enavate Sciences (a platform of Patient Square Capital) and ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min It’s one of the largest ...
Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.
Braveheart Bio has waded into the fight for a heart disease market, paying (PDF) $65 million upfront for a rival to Bristol Myers Squibb’s Camzyos and Cytokinetics’ aficamten. Jiangsu Hengrui ...
While "Braveheart" tells the tale of Scottish hero William Wallace, much of its powerful cinematography was captured on Irish soil. From Meath to Wicklow, Ireland stood in for medieval Scotland—and ...